Cell sheet containing mesenchymal stem cells
Mesenchymal stem cells are pluripotent cells capable of differentiating into myocardial and vascular endothelial cells. The present invention demonstrates that the mesenchymal stem cell sheet have therapeutic potential for a severely damaged heart due to its pluripotency and in situ self-renewal capability. Mesenchymal stem cells derived from adipose tissue were cultured to prepare a mesenchymal stem cell sheet. Four weeks after induction of myocardial infarction in rats, the mesenchymal stem cell sheet was transplanted to the heart. The mesenchymal stem cell sheet were readily engrafted to the surface of the scarred myocardium, grew gradually in situ, and formed a thick layer (approximately 600 μm) in 4 weeks. The grown transplanted mesenchymal tissue contained newly formed blood vessels, myocardial cells, and undifferentiated mesenchymal cells. The engrafted mesenchymal stem cells inhibited thinning of the myocardial wall in the scar area, and improved cardiac function and survival rate in rats with myocardial infarcts. Thus, mesenchymal stem cell sheet transplantation may represent a novel therapeutic approach for myocardial tissue regeneration.
1. A method for treating heart failure in a patient, comprising transplanting a single layer cell sheet for transplantation comprising aggregated confluent mesenchymal stem cells derived from adipose tissue on the epicardial surface of the heart of said patient, wherein the cell sheet will grow in the form of a layer with a thickness of 100 μm or more.
2. The method for treating heart failure in a patient according to claim 1 , wherein the cell sheet will grow in the form of a layer with a thickness of 100 μm to 600 μm.
3. A method for treating heart failure in a patient, comprising: transplanting a single layer cell sheet comprising aggregated mesenchymal stem cells derived from adipose tissue on the epicardial surface of the heart of said patient, wherein the cell sheet has the following properties:
(1) the ability to grow in situ to form a layer with a thickness of 100 μm or more,
(2) the stem cells will grow in situ to induce cardiac muscle and neovascularization,
(3) the stem cells will differentiate in situ into myocardial, vascular endothelial and vascular smooth muscle cells, and
(4) the mesenchymal stem cell sheet consists essentially of mesenchymal cells and optionally other cells differentiated from mesenchymal cells and optionally other contaminating cells which remain after collecting the mesenchymal stem cells.
4. The method for treating heart failure in a patient according to claim 3 , wherein said mesenchymal stem cell sheet consists of mesenchymal cells and optionally other cells differentiated from mesenchymal cells and optionally other contaminating cells which remain after collecting the mesenchymal stem cells.
5. The method for treating heart failure in a patient according to claim 3 or 4 , wherein said mesenchymal stem cells are autologous somatic stem cells obtained from said patient.
6. The method for treating heart failure in a patient according to claim 5 , wherein the cell sheet has the ability to grow in situ to form a layer with a thickness of 100 μm to 600 μm.
7. The method for treating heart failure in a patient, according to claim 3 , wherein the cell sheet is transplanted to the surface of an infarct lesion or scar tissue resulting from the infarct lesion.
8. The method for treating heart failure in a patient according to claim 3 , wherein the cell sheet is slid onto the surface of the heart.
9. The method for treating heart failure in a patient according to claim 1 , wherein the cell sheet is transplanted on the surface of an infarct lesion of a chronic heart failure patient.
10. The method for treating heart failure in a patient according to claim 3 , wherein the cell sheet is transplanted on the surface of an infarct lesion of a chronic heart failure patient.
11. The method for treating heart failure in a patient according to claim 3 , wherein the cell sheet comprising aggregated mesenchymal stem cells exhibits (a) significantly higher mean arterial pressure, and (b) significantly higher weight gain than in an untreated control group at 4 weeks after transplantation.